Printer Friendly

A Systematic Review and Meta-Analysis on the Treatment of Cerebral Hemorrhage with NaoXueShu Oral Liquid.

1. Introduction

Intracerebral hemorrhage is a primary nontraumatic hemorrhage, commonly caused by high blood pressure. The mortality rate of patients with cerebral hemorrhage can reach 40% to 50%, and 75% of the survivors cannot live independently after 1 year, which seriously affects quality of life [1]. The main reason for cerebral hemorrhage with high mortality and high disability rates is cerebral edema after brain injury. It affects normal nerve function, increases intracranial pressure, and can form severe cerebral hernia when intracranial pressure increases. Therefore, it is very important to carry out early intervention for patients with cerebral hemorrhage.

NaoXueShu oral liquid's main ingredients include astragalus root, leech, calamus, Achyranthes, and Rhizoma Chuanxiong; it is intended to replenish Qi and activate blood and remove blood stasis and is mainly used for hemorrhagic stroke in patients with Qi deficiency and blood stasis. It was developed according to the theory that "Qi is the commander of blood; blood is the mother of Qi" [2]. Astragalus is commonly used in Chinese medicine Yiqi, and modern research shows that astragalus can reduce brain damage of neuronal mitochondria after hemorrhage, inhibit neuronal apoptosis, and promote the recovery of neurological function. Moreover, astragalus can also protect the blood-brain barrier permeability, perform antioxidation, and prevent cerebral ischemia [3-5]. Leech has a broken blood and blood stasis-eliminating effect; modern research shows that leech has a cerebral protective effect of anticoagulation, inhibiting platelet aggregation, improving blood rheology, and relieving acute brain injury and brain edema, among other benefits [6-8].

In recent years, experiments have shown that NaoXueShu oral liquid on cerebral vascular disease, especially in the treatment of cerebral hemorrhage, has shown advantages: it can regulate the expression of neuroprotective factor-related protein, reduce the release of inflammatory factors, inhibit free radical damage, inhibit apoptosis, thereby reducing the volume of hematoma, and alleviate cerebral edema. Improving cerebral energy metabolism promotes nerve function repair [9-13].

Modern medicine posits that the key to treating cerebral hemorrhage is to control hypertension, and we are currently studying whether calcium channel blockers, statins, endothelin receptor antagonists, magnesium, erythropoietin, and other drugs can prevent or reverse cerebral hemorrhage; however, evidence is still lacking [14, 15]. In recent years, NaoXueShu oral liquid has been widely used in clinics. Studies found that it can obviously promote the absorption of intracranial hematoma in the treatment of cerebral hemorrhage [16]; promote the recovery of neurological function, especially affecting the treatment of apoplectic aphasia [17-19]; improve blood flow; reduce inflammatory response; effectively reduce brain edema; reduce intracranial pressure; improve the prognosis of patients; reduce the disability rate; and improve the survival rate [20-22].

This study's purpose is to conduct a comprehensive systematic review and evaluate the therapeutic effect of NaoXueShu oral liquid for treating cerebral hemorrhage.

2. Methods

This systematic review was conducted in accordance with the guidelines for systematic review and meta-analysis of the preferred reporting items. This systematic study does not require an ethical review.

2.1. Databases and Retrieval Strategies. In this study, the Chinese National Knowledge Infrastructure (CNKI), the Chinese Scientific Journal Database, the Chinese Biomedical Literature (CBMdisc), Wanfang database, EMbase, PubMed, and the Cochrane database were searched for original studies and search was conducted in January 2017. The other related research studies were manually retrieved. The following key words were used alone or in combination: "NaoXueShu"; "NaoXueShu injection"; "nxst"; "cerebral hemorrhage"; "hemorrhagic stroke"; "hemorrhagic apoplexy."

More studies were also searched for in the selected references. In addition, we used a flow chart to make the search process more rigorous and detailed (Figure 1).

2.2. Inclusion and Exclusion Criteria

2.2.1. Inclusion Criteria. The literature had no special requirements on the language, demographic characteristics, and types of publications. The included patients were not more than 80 years old, and the amount of bleeding was less than 50 mL; moreover, the patients had the basic clinical symptoms of cerebral hemorrhage and, after CT imaging examination, adhered to the clinical diagnostic criteria of cerebral hemorrhage. Oral administration of NaoXueShu oral liquid was 10 mL, oral or nasal feeding, 3 times a day, 1 month as a course of treatment. In the included randomized controlled trials (RCTs), the patients were treated with NaoXueShu alone or in combination with other drugs for treating cerebral hemorrhage. The literature included National Institutes of Health Stroke Scale (NIHSS) score combined with neurologic deficit or corresponding disease diagnostic criteria. The results of the first, second, and third were the efficacy evaluation, NIHSS score at 2 weeks and 4 weeks (in the literature there are descriptive differences of 30 days, 4 weeks, and 1 month; for the convenience of statistics, all of them were unified for 4 weeks), hematoma volume, BI, and GCS.

2.2.2. Exclusion Criteria. We excluded repeat publications in the same group of patients.

2.3. Data Screening and Quality Evaluation. We searched 513 published articles about NaoXueShu treatment of cerebral hemorrhage in 7 databases and excluded the literature that was not consistent and repeated. The remaining 24 articles were screened according to the following criteria: (1) whether the literature focused on patients with cerebral hemorrhage; (2) whether the included samples were randomized controlled studies; (3) whether the final study index of the literature met the requirements; (4) whether the grouping of the literature was scientific; (5) the author's experience of the literature; (6) the published year of the literature. Finally, we got 14 papers. Two authors (Lijun Wu and Xiaofeng Wang) independently performed the literature search, selection, and the data exaction. Any disagreements were discussed, and if the discussion did not yield a final decision, the 3rd author (Xiaomeng Ren) was invited to make a decision. The information included the following: title, author, publication time, literature sources, research scale, number of cases, diagnostic criteria, research methods, and treatment process. We also considered the control group, the results, and adverse reactions. To ensure the quality of the included literature, we used RevMan 5.3.0 software to evaluate the studies systematically and comprehensively. Eventually we obtained the "risk of bias graph" and "risk of bias summary" (Figures 2 and 3). The reliability of the results was further verified by using the forest map to evaluate the efficacy and the funnel plot to evaluate the publication bias.

2.4. Statistical Analysis. The RevMan 5.3 software provided by the Cochrane Collaboration was used for data analysis, and, through the study of the content and research indicators for classification, the final packet data entry was carried on. Dichotomous data were expressed as relative risk (RR); continuous outcomes were presented as weighted mean difference (WMD); and the 95% confidence intervals (CIs) were calculated for both. The meta-analysis was performed if the intervention and control groups, as well as the outcomes, were the same or similar. For the significant efficiency, we used Barthel index (BI), the odds ratio (OR) value, hematoma volume, NIHSS score, and Glasgow coma score (GCS), score mean difference (MD) value. According to the results of [I.sup.2], we analyzed the data using random ([I.sup.2] > 50%, heterogeneity) or fixed effects model ([I.sup.2] < 50%).

3. Result

A total of 14 studies were incorporated into the information integration (Table 1) [16-18, 20, 21, 23-31].

3.1. Characteristics of Included Studies. Initially, we retrieved 513 articles from 7 common databases. At present, NaoXueShu is mainly used in China clinical practice. We collected most of the articles from the Wanfang database and CNKI. In all the articles collected, we excluded duplicate, nonconforming, incomplete data. In addition, according to our requirements, 14 papers were included in the study. All the articles focused on treating cerebral hemorrhage in patients with NaoXueShu.

3.2. Methodologic Quality of Included Studies. The selected articles were all screened and belonged to RCT literatures. By choosing 14 articles, we were able to consider a sample size greater than 30 cases. In the 14 articles, 10 were randomized by more scientific methods, including the use of blind method for 3 articles. In the literature, patients in the observation group and the control group had clear inclusion criteria or the patients' data were initially analyzed statistically, if not statistically significant, to be included in the control group. We also objectively analyzed the offset risk, and we evaluated the offset of each article according to the relevant criteria of the offset table. In this process, we tried be objective and fair, especially in the "other biases" column. We were particularly concerned that the 14 articles included the presence of drug promotion of the subjects and made an objective evaluation.

3.3. Effects of Interventions

3.3.1. Comparison of Hematoma Volume Change. The following 5 RCTs showed that NaoXueShu can effectively reduce cerebral hemorrhage and had statistical significance (n = 509; MD, -3.82; 95% CI, -7.32~-0.31; [I.sup.2] = 97%; P = 0.03; Figure 4).

3.3.2. GCS Comparison. The following 2 RCTs showed that NaoXueShu had a certain effect in treating cerebral hematoma, had obvious function of arousal, and had statistical significance (n = 198; OR, 1.49; 95% CI, 1.06~1.92; [I.sup.2] = 3%; P < 0.00001; Figure 5).

3.3.3. NIHSS Score Comparison. The following 7 RCTs showed NaoXueShu oral liquid's effect on cerebral hemorrhage after 2 weeks and 4 weeks of nerve function protection. The results showed that, 2 weeks after treatment of cerebral hemorrhage, the difference was not statistically significant (P > 0.05), indicating that NaoXueShu did not show a significant effect in 2 weeks. But, after 4 weeks of treatment, NaoXueShu can improve nerve function to a certain extent and had statistical significance (n = 318; MD; -0.62 95% CI; -1.25~0.02; [I.sup.2] = 0%; P = 0.06; Figure 6) (n = 574; MD; -2.68; 95% CI -4.77~-0.59; [I.sup.2] = 94%; P = 0.01; Figure 7). In a comparison of 2 and 4 weeks of treatment, after cerebral hemorrhage, P value gets smaller and smaller, which showed that the difference between the treatment group and the control group increases.

3.3.4. BI Comparison. The following 2 RCTs showed that NaoXueShu had a certain effect in treating cerebral hematoma, and it can obviously improve the patient's quality of life and had statistical significance (n = 237; OR, 2.47; 95% CI, 1.46~4.18; [I.sup.2] = 0%; P = 0.0007; Figure 8).

3.3.5. Efficacy Comparison. The following 6 RCTs showed a good effect in treating cerebral hemorrhage compared with the control group and had statistical significance (n = 814; OR, 3.16; 95% CI, 2.09~4.76; [I.sup.2] = 0%; P < 0.00001; Figure 9).

3.3.6. Adverse Reactions. Included in the 14 articles, 2 RCTs were related to adverse reactions, neither of which mentioned the adverse effects of NaoXueShu, which meant this drug had no obvious side effects so far. Therefore, the authenticity and scientific nature of the literature, as well as the integrity of the information provided, have some credibility.

3.3.7. Publication Bias. We used Stata software to evaluate the articles' publication bias. Because the indicators of GCS and the BI had only two included RCTs, did not meet the standard of the funnel map, and were without special significance, we conducted the migration analysis to the other 4 indexes and used the Egger method to conduct the diagnosis analysis. The results were shown as in Figure 10 and Table 2.

We used Stata software to conduct migration analysis on the included articles. The results showed that the hematoma volume, NIHSS score at 2 weeks, and efficiency comparison were not offset (P > 0.05), while the NIHSS score at 4 weeks shows a slight deviation (P < 0.05). Based on this, an NIHSS score at 4 weeks of the literature was removed one by one. We eventually found that when deleting the study by Wang and Zhao [16], the heterogeneity was significantly reduced (from 94% to 19%) and P value was increased, indicating that the literature shows an offset in the efficiency comparison.

4. Discussion

Cerebral hemorrhage is a common cerebrovascular disease, commonly caused by hypertension. Primitive hematoma first appears after intracerebral hemorrhage, and the hematoma's location and size are closely related to the prognosis, then perihematoma accompanied the emergence of edema. Decreased cerebral blood flow from the perihematoma or peripheral lesion may result in decreased oxygen extraction fraction and tissue ischemic injury, which may be related to the inflammatory process induced by the hematoma [32, 33]. Cerebral hemorrhage and cerebral ischemia belong to the category of "stroke" in the field of Chinese medicine. Chinese medicine's definition of stroke is based on the deficiency of Qi and blood loss because of internal root, emotional disorders, eating Feiganhouwei, or excessive alcohol and tobacco use, causing the imbalance of yin and Yang and reversal of Qi and blood, blood stasis, or blood overflow pulse; therefore, Qi deficiency and blood stasis are the main mechanisms of acute stage and early recovery. NaoXueShu oral liquid's main ingredients include astragalus root, leech, calamus, Achyranthes, and Rhizoma Chuanxiong, with the effect of tonifying Qi, activating blood, and removing blood stasis. It is suitable for treating cerebral hemorrhage.

NaoXueShu oral liquid is relatively extensive in clinical application. Relevant literature can be found about NaoXueShu, among which the clinical research literature was far greater than experimental studies. This document's purpose is to understand the NaoXueShu's effect of the treatment of cerebral hemorrhage. We divided the literature into five categories: volume of hematoma, GCS, BI, NIHSS score of the patients in each stage (for a period of 2 weeks and 4 weeks), and the curative effect.

There are some advantages and disadvantages of the meta-analysis and the system evaluation: we had a detailed record of the process of selecting the documents. Most included literature was published in Chinese journals. In addition to a small part of the poor quality of literature, most literature was published in more well-known publications with recent publication years. Besides Xie et al. [25] and Lu et al. [27], which were published before 2010, other literatures were published after 2010. In addition, the evaluation system still has many deficiencies: the quality of literature was low, the content was not comprehensive enough (e.g., most of the included RCTs were without follow-up and adverse reactions), and assessment of the neurological function score may be influenced by the subjective factors in the process; therefore, the consistency of the data may differ between documents.

[I.sup.2] is a measure of heterogeneity. The greater [I.sup.2], the greater the heterogeneity [34]. According to the statistical results, the heterogeneity of hematoma volume (Figure 4) and NIHSS score at 4 weeks (Figure 7) was 97% and 94%, respectively. The reasons for the high heterogeneity may be related to the number of samples, the quality of the literature, the subject of study, and the duration of treatment. In addition, compared with the two classification variables, high heterogeneity is more common in continuous variables [35], and the volume of hematoma and NIHSS score at 4 weeks were continuous variables, and the possibility of heterogeneity was relatively large. Other GCS of 2 weeks (Figure 5), NIHSS score of 2 weeks (Figure 6), BI of 90 days (Figure 8), and evaluation of the effect (Figure 9) were 3%, 0%, 0%, and 0%, respectively; since they were less than 50%, or even close to 0%, these outcomes cannot have obvious heterogeneity and the results were reliable and relatively stable. However, although there are two indicators of heterogeneity, P value of each index is less than 0.05, indicating that the study of NaoXueShu oral liquid in the above indicators is statistically significant.

5. Conclusion

NaoXueShu oral liquid is made of BuYangHuanWu decoction from The Errors in Medicine Corrected and Rhubarb Magic Pill from the Golden Chamber. It is mainly used for removing blood stasis, supplementing tonifying Qi, and activating blood circulation. According to the pathogenesis, "where the bleeding must leave the meridians, blood stasis is left meridian" and the guidelines that state, "Qi is the commander of blood, blood is the mother of Qi, blood gas runs, qi stagnation and blood stasis." NaoXueShu mainly treated stroke with Qi deficiency and blood stasis. In recent years, it has often been used to treat cerebrovascular disease, and the experimental results show that NaoXueShu oral liquid can obviously improve cerebral microcirculation, inhibit apoptosis, and inhibit oxygen free radicals and protect brain cells function. Clinical study also showed that NaoXueShu oral liquid can reduce the volume of hematoma, improve the recovery of nerve function, reduce brain edema, relieve inflammatory reaction, and promote the prognosis of patients with cerebral hemorrhage.

In conclusion, according to preliminary statistics and evaluation of 14 included studies, we concluded the following: NaoXueShu oral liquid in the treatment of acute cerebral hemorrhage had more obvious effects than conventional medical treatment (P < 0.01). To a certain extent, it can promote the absorption of hematoma in the brain and then rapidly reduce the brain hematoma volume (P < 0.05); however, Wang and Zhao [16] suggested that the absorption of intracranial hematoma did not represent an improvement in clinical outcome. Compared with the control group, there was no obvious advantage in the treatment of cerebral hemorrhage from 2 weeks with NIHSS (P > 0.05). However, compared with the NIHSS (P < 0.05) of 4 weeks and BI (P < 0.01) after 90 days, we found that NaoXueShu oral liquid can reduce the neurological damage and improve the prognosis. With NaoXueShu, drug taking time prolonged and the differences between the two groups increased gradually, which showed that long-term use can improve the neurological dysfunction of patients and their quality of life and living ability.

ACH:        Acute cerebral hemorrhage
BI:         Barthel Index
CNKI:       Chinese National Knowledge Infrastructure
CBMdisc:    Chinese Biomedical Literature Database
CT:         Computer Tomography
CI:         Confidence interval
CH:         Cerebral hemorrhage
Coef.:      Coefficient
GCS:        Glasgow coma scores
HICH:       Hypertensive intracerebral hematoma
HS:         Hemorrhagic stroke
MD:         Mean difference
mRS:        Modified Rankin scale
NIHSS:      National Institutes of Health Stroke Scale
OR:         Odds ratio
RCTs:       Randomized controlled trials
RR:         Relative risk
Std. Eff.:  Standard Effect
Std. Err.:  Standard Error
TCM:        Traditional Chinese Medicine
VIP:        The Chinese Scientific Journal Database
WMD:        Weighted mean difference
WHO:        World Health Organization
WAB:        Western aphasia battery
ESS:        European Stroke Scale.

Conflicts of Interest

The authors declared that there are no conflicts of interest.

Authors' Contributions

Lijun Wu, Yanda Li, Xiaofeng Wang, Xiaomeng Ren, and Haiyan Zhu contributed equally to this work.


This study was supported by the National Natural Science Foundation of China (no. 81673899) and the outstanding project of Beijing University of Chinese Medicine (2015-JYB-XJQ001).


[1] D. Klebe, D. McBride, J. J. Flores, J. H. Zhang, and J. Tang, "Modulating the immune response towards a neuroregenerative peri-injury milieu after cerebral hemorrhage," Journal of Neuroimmune Pharmacology, vol. 10, no. 4, pp. 576-586, 2015.

[2] C. Chen, L. X. Yuan, and G. M. Zhang, "Clinical application and experimental research progress of nao-xue-shu oral liquid in cerebrovascular disease," Chinese Journal of Integrated Traditional Chinese and Western Medicine, vol. 12, no. 8, pp. 1005-1006, 2014.

[3] D. K. Wang, H. Y. Zhang, H. Y. Liu et al., "Analyses on stereology of mitochondrion of neurons that surround intracerebral hemorrhage in rats and the neuroprotective effect of astragalus injection for intracerebral hemorrhage," Chinese Journal of Clinical Anatomy, vol. 31, no. 6, pp. 692-695, 2013.

[4] H. Y. Liu, Z. Sun, D. K. Wang et al., "The inhibition of astragalus and salviae miltiorrhizae injection on the neuronal apoptosis of the penumbra around the intracerebral hemorrhage in rats," Lishizhen Medicine and Materia Medica Research, vol. 23, no. 8, pp. 1892-1895, 2012.

[5] J. Cai, R. Pan, X. Jia et al., "The combination of astragalus membranaceus and ligustrazine ameliorates micro-haemorrhage by maintaining blood-brain barrier integrity in cerebrally ischaemic rats," Journal ofEthnopharmacology, no. 158, pp. 301-309, 2014.

[6] K. M. Li, G. Zhang, and J. B. Wu, "Overview of pharmacological research of leech," Traditional Chinese Medicine Research, vol. 20, no. 2, pp. 62-64, 2007.

[7] Y. Zhang, J. C. Feng, J. Wu et al., "Protective effects of hirudin on acute experimental intracerebral hemorrhage," China Journal of Chinese Materia Medica, vol. 31, no. 1, pp. 69-72, 2006.

[8] H. Dong, J. X. Ren, J. J. Wang et al., "Chinese medicinal leech: ethnopharmacology, phytochemistry, and pharmacological activities," Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 7895935, 11 pages, 2016.

[9] X. Ai and C. Liu, "Effect of nao-xue-shu oral liquid on the volume of hematoma in rats with cerebral hemorrhage and the protective effect of nerve function," Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, vol. 12, no. 7, pp. 859-861, 2014.

[10] L. Sun, Y. B. Liu, L. Wanget al., "Effect of Astragalus Injection on expression of BDNF in cerebral ischemia reperfusion injury in rats," World Chinese Medicine, vol. 11, no. 4, pp. 686-689, 2016.

[11] B. Chen, X. Y. Miao, and W. Shi, "Effect of Naoxueshu on the expression of esopageal cancer related gene 4 in choroid plexus epithelial cells in intracerebral hemorrhage rats," China Medicine, vol. 11, no. 11, pp. 1713-1717, 2016.

[12] Y. Hu, Y. H. Zhang, and C. X. Liu, "Effects of Nao-Xue-Shu oral liquid on cerebral function and apoptosis of peripheral penumbra after intracerebral hemorrhage in rats," Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, vol. 14, no. 15, pp. 1735-1737, 2016.

[13] X. Ai and C. Liu, "Neuroprotective effects of Nao-Xue-Shu oral liquid on acute cerebral infarction in rats," Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, vol. 13, no. 11, pp. 1278-1280, 2015.

[14] P. Adamczyk, S. He, A. P. Amar, and W. J. Mack, "Medical management of cerebral vasospasm following aneurysmal subarachnoid hemorrhage: a review of current and emerging therapeutic interventions," Neurology Research International, vol. 2013, Article ID 462491,10 pages, 2013.

[15] G. Grasso, C. Alafaci, R. L. Macdonald et al., "Management of aneurysmal subarachnoid hemorrhage: state of the art and future perspectives," Surgical Neurol Internation, no. 8, p. 11, 2017.

[16] X. G. Wang and X. Q. Zhao, "Paired study on the treatment of acute cerebral hemorrhage with nao-xue-shu oral liquid," Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, vol. 13, no. 7, pp. 937-938, 2015.

[17] S. J. Chen, H. Y. Wang, Y. Zuo et al., "Clinical observation on the treatment of secondary brain damage after intracerebral hemorrhage by Nao-Xue-Shu oral liquid," Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, vol. 14, no. 2, pp. 199-202, 2016.

[18] M. Z. Wang, L. Zhang, W. F. Jiang et al., "Clinical observation of nourishing qi, resolving stagnation, cooling blood and eliminating-phlegm method in treating aphasia of mixed stroke," Journal of Shanghai University of Traditional Chinese Medicine, vol. 29, no. 3, pp. 23-26, 2015.

[19] Y. Yan, M. Wang, L. Zhang et al., "Nao-Xue-Shu oral liquid improves aphasia of mixed stroke," Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 709568, 6 pages, 2015.

[20] X. W. Zhou, Y. Zuo, S. J. Chen et al., "Observation of clinical effect of nao-xue-shu oral liquid on patients with basal ganglia hemorrhage," Shaanxi Medical Journal, vol. 44, no. 7, pp. 866-867, 2015.

[21] Y. Q. Yang and T. Xue, "Clinical study on naoxueshu oral liquid combined with nimodipine in treatment of hypertensive cerebral hemorrhage," Drugs & Clinic, vol. 30, no. 11, pp. 1341-1344, 2015.

[22] H. Jiang, Y. Qin, T. Liu et al., "Nao-xue-shu oral liquid protects and improves secondary brain insults of hypertensive cerebral hemorrhage," Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 9121843, 6 pages, 2016.

[23] Y. Yuan and D. Yuan, "HuoxueYiqi huatan qingre treatment of hemorrhagic stroke clinical research," Chinese Journal of Aesthetic Medicine, vol. 21, no. 9, pp. 189-190, 2012.

[24] S. X. Wang, R. X. Song, Z. Wang et al., "Evaluation of clinical effect of naoxueshu oral liquid on hematoma absorption," Chinese Journal ofIntegrative Medicine on Cardio-/Cerebrovascular Disease, vol. 12, no. 4, pp. 452-453, 2014.

[25] D. Z. Xie, B. Y. Xu, Y. Sun et al., "Naoxueshu Liquid for Hemorrhagic Stroke," Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease Journal, vol. 5, no. 8, pp. 690-691, 2007.

[26] W. C. Miao and R. Yan, "Clinical observation on the treatment of hypertensive cerebral hemorrhage with naoxueshu oral liquid," Chinese Journal of Practical Nervous Diseases, vol. 17, no. 14, pp. 102-103, 2014.

[27] M. Lu, R. P. Xie, and Y. Fu, "Effect of naoxueshu oral liquid on cerebral hemorrhage caused by hypertension," Chinese Journal of Rehabilitation Theory and Practice, vol. 10, no. 5, pp. 304-305, 2004.

[28] Y. Y. Gu and Y. Ma, "Naoxueshu oral liquid for the treatment of cerebral hemorrhage in 32 cases," Henan Traditional Chinese Medicine, vol. 30, no. 10, pp. 982-983, 2010.

[29] Z. Y. Wang and Z. C. Ding, "Application of huoxue yiqi huatan tongluo treatment of cerebral hemorrhage in patients with clinical observation," Contemporary Medicine Forum, vol. 12, p. 8, 2014.

[30] H. Wang, X. Z. Niu, and T. S. Su, "Clinical observation on the treatment of cerebral hemorrhage in convalescent stage with acupuncture combined with naoxueshu oral liquid," World Latest Medicine Information, vol. 16, no. 3, pp. 110-111, 2016.

[31] S. H. Li, X. H. Han, G. Y. Jiang et al., "Clinical observation on the treatment of hypertensive cerebral hemorrhage with minimally invasive surgery of intracranial hematoma combined with naoxueshu oral liquid," Chinese Journal of Practical Nervous Diseases, vol. 17, no. 17, pp. 82-83, 2014.

[32] C. Herweh, E. Juttler, P. D. Schellinger et al., "Evidence against a perihemorrhagic penumbra provided by perfusion computed tomography," Stroke, vol. 38, no. 11, pp. 2941-2947, 2007.

[33] H. B. Brouwers and J. N. Goldstein, "Therapeutic strategies in acute intracerebral hemorrhage," Neurotherapeutics, vol. 9, no. 1, pp. 87-98, 2012.

[34] D. Wang, J. X. Zhai, Z. Y. Mou et al., "Discussing on the research of heterogeneity in meta-analysis," Chinese Journal of Evidence-Based Medicine, vol. 9, no. 10, pp. 1115-1118, 2009.

[35] A. C. Alba, P. E. Alexander, J. Chang, J. Macisaac, S. Defry, and G. H. Guyatt, "High statistical heterogeneity is more frequent in meta-analysis of continuous than binary outcomes," Journal of Clinical Epidemiology, vol. 70, pp. 129-135, 2016.

Lijun Wu, (1, 2) Yanda Li, (3, 4) Xiaofeng Wang, (1) Xiaomeng Ren, (1) Haiyan Zhu, (1) Yikun Sun, (1) Yanwei Xing, (4) Lingqun Zhu, (1) Yonghong Gao, (1) and Hongcai Shang (1)

(1) Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Key Office of Encephalopathy TCM Research, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China

(2) Weishi Hospital of Traditional Chinese Medicine, Henan 475500, China

(3) Beijing University of Chinese Medicine, Beijing 100029, China

(4) Guang An Men Hospital, China Academy of Chinese Medical Science, Beijing 100053, China

Correspondence should be addressed to Yonghong Gao; and Hongcai Shang;

Received 13 February 2017; Accepted 16 April 2017; Published 29 May 2017

Academic Editor: Alexander N. Orekhov

Caption: Figure 1: Flow diagram of the systematic review.

Caption: Figure 2: Risk of bias graph. Each item was evaluated as a percentage of the literature, and the quality of the selected literature was evaluated according to the Cochrane criteria.

Caption: Figure 3: Risk of bias summary: review authors' judgments about each risk of bias item for each included study.

Caption: Figure 10: Funnel plots. ((a) Comparison othematoma volume; (b) NIHSS score comparison at 2 weeks; (c) NIHSS score comparison at 4 weeks; (d) treatment efficiency comparison).
Table 1: Characteristics of included studies.


Study                 Sample size     Diagnosis      Treatment

Y. Yuan and D.        60 (36; 24)         CH        NaoXueShu +
Yuan 2012 [23]                                        routine

Wang et al.          122 (64; 58)        HICH       NaoXueShu +
2014 [24]                                             routine

Xie et al. 2007     440 (310; 130)        HS         NaoXueShu

Miao and Yan          69 (35:34)         HICH       NaoXueShu +
2014 [26]                                             routine

Lu et al. 2004       140 (70; 70)        HICH        NaoXueShu

Wang and Zhao         30 (15; 15)        ACH        NaoXueShu +
2015 [16]                                             routine

Gu and Ma 2010        62 (32; 30)         CH        NaoXueShu +
[28]                                                  routine

Chen et al.           67 (35; 32)        HICH       NaoXueShu +
2016 [17]                                             routine

Wang and Ding         86 (43; 43)         CH        NaoXueShu +
2014 (2) [29]                                         routine

Wang et al.           96 (48; 48)        HICH       NaoXueShu +
2016 [30]                                          acupuncture +

Wang et al.          102 (51; 51)       Mixed       NaoXueShu +
2015 (2) [18]                           stroke        routine

Zhou et al.          170 (87; 83)         CH        NaoXueShu +
2015 [20]                                             routine

Li et al. 2014        76 (39; 37)        HICH       NaoXueShu +
[31]                                                  routine

Yang and Xue          86 (43; 43)        HICH       NaoXueShu +
2015 [21]                                             routine


Study                  Control       Treatment        Clinical
                                       course         standards

Y. Yuan and D.       Naoxuekang +     30 days      The standard of
Yuan 2012 [23]       Conventional                  TCM and Western
                      treatment                       medicine

Wang et al.          Conventional     4 weeks      CH + standards
2014 [24]             treatment                         (95)

Xie et al. 2007       Naoxuekang      30 days      TCM diagnostic
[25]                                                  code (96)

Miao and Yan         Conventional     4 weeks       CH standards
2014 [26]             treatment                       (95) + CT

Lu et al. 2004        Naoxuekang      1 month        Cranial CT

Wang and Zhao        Conventional     1 month            WHO
2015 [16]             treatment                     diagnostics;
                                                   CT; diagnostic
                                                     criteria of
                                                      stroke in

Gu and Ma 2010       Conventional     1 month       CH standards
[28]                  treatment                         (95)

Chen et al.          Conventional     90 days            CT
2016 [17]             treatment

Wang and Ding        Naoxuekang +     1 month         Relevant
2014 (2) [29]        Conventional                   standards of
                      treatment                    the Ministry of
                                                     Health and
                                                    criteria for
                                                    diagnosis and
                                                    treatment of

Wang et al.         Acupuncture +     1 month      Guidelines for
2016 [30]              routine                     prevention and
                                                    treatment of
                                                     diseases in
                                                    China (2005)

Wang et al.          Conventional     4 weeks       CT and/or MRI
2015 (2) [18]         treatment

Zhou et al.          Conventional     90 days            CT
2015 [20]             treatment

Li et al. 2014       Conventional     2 weeks            CT
[31]                  treatment

Yang and Xue         Conventional     4 weeks       CH standards
2015 [21]             treatment                         (95)

Study                Outcome measure

Y. Yuan and D.          Curative
Yuan 2012 [23]           effect;
                     rate; integral
                        value of
                     integral value
                         of TCM

Wang et al.           GCS score; BI
2014 [24]            score; hematoma

Xie et al. 2007       stroke score;
[25]                    hematoma

Miao and Yan         NIHSS score and
2014 [26]            curative effect

Lu et al. 2004       Changes in TCM
[27]                 syndrome score;
                      NIH integral

Wang and Zhao           Hematoma
2015 [16]            uptake; stroke
                      score, NIHSS;
                       3-month mRS

Gu and Ma 2010        Neurological
[28]                 deficit score;

Chen et al.             Curative
2016 [17]                effect;
                     hematoma volume
                      (10, 20, 25)

Wang and Ding           Curative
2014 (2) [29]            effect;
                     hematoma volume

Wang et al.          NIHSS score; BI
2016 [30]                 score

Wang et al.          WAB score; mRS
2015 (2) [18]         score; NIHSS
                       fibrin, red
                       blood cell

Zhou et al.               ESS;
2015 [20]             Neurological
                     deficit score;
                        BI score

Li et al. 2014         GCS score;
[31]                  Neurological
                      deficit score

Yang and Xue          NIHSS score;
2015 [21]               curative

Table 2: Egger's test of publication bias.

Outcome        Std. Eff.       Coef.       Std. Err.      t     P > t

Hematoma         Slope       0.6955327     0.5746734    1.21    0.313
volume            Bias       -7.826066     3.376481     -2.32   0.103

NIHSS-2w         Slope      -0.3706095     0.6525846    -0.57   0.627
                  Bias       0.6525892     2.897941     0.23    0.843

NIHSS-4w         Slope       2.208923      1.010601     2.19    0.094
                  Bias       -13.91488      4.82455     -2.88   0.045

Efficiency       Slope      -0.1368343    -0.0662528    -2.07   0.108
                  Bias      -0.1644329     0.244169     -0.67   0.538

Outcome        Std. Eff.            [95% CI]

Hematoma         Slope       -1.133334      2.5244
volume            Bias       -18.57153     2.919403

NIHSS-2w         Slope       -3.178454     2.437235
                  Bias       -11.81624     13.12142

NIHSS-4w         Slope      -0.5969561     5.014802
                  Bias       -27.30998    -0.5197859

Efficiency       Slope      -0.3207815     -0.047113
                  Bias      -0.8423548     0.5134891

Figure 4: Comparison of hematoma volume.

                            Naoxueshu             Control
Study or subgroup
                       Mean    SD    Total   Mean     SD    Total

Lu et al. 2004         6.58   5.15    70     8.77    5.2     70
Xie et al. 2007        6.58   5.15    310    7.77    5.2     130
Wang et al. 2014        5     1.25    64       7     2.53    58
Wang and Zhao 2015     11.6   8.5     30     14.5    9.4     30
Chen et al. 2016       4.69   1.38    35     15.31   3.64    32

Total (95% CI)                        509                    320

Study or subgroup      Weight        Mean Difference
                                    IV, random, 95% CI      Year

Lu et al. 2004          20.6%       -2.19 [-3.90, -0.48]    2004
Xie et al. 2007         21.2%       -1.19 [-2.25, -0.13]    2007
Wang et al. 2014        21.4%       -2.00 [-2.72, -1.28]    2014
Wang and Zhao 2015      15.9%        -2.90 [-7.43, 1.63]    2015
Chen et al. 2016        21.0%     -10.62 [-11.96, -9.28]    2016

Total (95% CI)         100.0%       -3.82 [-7.32, -0.31]

Heterogeneity: [[tau].sup.2] = 14.80; [chi square] = 143.21,
df = 4 (P < 0.00001); [I.sup.2] = 97%

Test for overall effect: Z = 2.13 (P = 0.03)

Figure 5: GCS comparison at 2 weeks.

                            Naoxueshu              Control
Study or subgroup
                      Mean     SD    Total   Mean     SD    Total

Li et al. 2014        14.08   0.84    39     12.49   1.21    37
Wang et al. 2014       12     3.25    64      11     2.58    58

Total (95% CI)                        103                    95

Study or subgroup     Weight      Mean difference
                                 IV, fixed, 95% CI

Li et al. 2014         82.9%      1.59 [1.12, 2.06]
Wang et al. 2014       17.1%     1.00 [-0.04, 2.04]

Total (95% CI)        100.0%      1.49 [1.06, 1.92]

Heterogeneity: [chi square] = 1.03, df = 1 (P = 0.31); [I.sup.2] = 3%

Test for overall effect: Z = 6.81 (P < 0.00001)

Figure 6: NIHSS score comparison at 2 weeks.

                             Naoxueshu             Control
Study or subgroup
                        Mean     SD    Total  Mean     SD    Total

Miao and Yan 2014       16.12   1.81    35    16.73   1.95    34
Wang and Zhao 2015      12.7    4.5     30    13.2    5.1     30
Wang et al. 2015 (2)    8.72    7.09    48    10.57   4.81    45
Wang et al. 2016        3.56    2.49    48    3.97    2.87    48

Total (95% CI)                          161                   157

Study or subgroup       Weight       Mean difference
                                    IV, random, 95% CI

Miao and Yan 2014        51.3%      -0.61 [-1.50, 0.28]
Wang and Zhao 2015       6.8%       -0.50 [-2.93, 1.93]
Wang et al. 2015 (2)     6.8%       -1.85 [-4.30, 0.60]
Wang et al. 2016         35.1%      -0.41 [-1.48, 0.66]

Total (95% CI)          100.0%      -0.62 [-1.25, 0.02]

Heterogeneity: [[tau].sup.2] = 0.00; [chi square] = 1.13,
df = 3 (P = 0.77); [I.sup.2] = 0%

Test for overall effect: Z = 1.90 (P = 0.06)

Figure 7: NIHSS score comparison at 4 weeks.

Study or subgroup
                             Mean   SD     Total

Lu et al. 2004               8.56   4.54    70
Miao and Yan 2014            6.61   2.19    35
Wang et al. 2015 (2)         5.89   5.74    48
Wang et al. 2016             1.97   1.02    48
Yang and Xue 2015            9.37   2.32    43
Y. Yuan and D. Yuan 2012     5.73   4.88    60
Total (95% CI)                              304

Study or subgroup                                   Weight
                             Mean     SD    Total

Lu et al. 2004               10.67   5.38    70      16.6%
Miao and Yan 2014            7.85    2.63    34      17.5%
Wang et al. 2015 (2)         9.69    7.31    45      14.2%
Wang et al. 2016             3.01    2.01    48      18.2%
Yang and Xue 2015            15.87   2.53    43      17.7%
Y. Yuan and D. Yuan 2012     7.22    4.23    30      15.9%
Total (95% CI)                               270    100.0%

Study or subgroup                Mean difference
                               IV, random, 95% CI

Lu et al. 2004                 -2.11 [-3.76, -0.46]
Miao and Yan 2014              -1.24 [-2.38, -0.10]
Wang et al. 2015 (2)           -3.80 [-6.48, -1.12]
Wang et al. 2016               -1.04 [-1.68, -0.40]
Yang and Xue 2015              -6.50 [-7.53, -5.47]
Y. Yuan and D. Yuan 2012        -1.49 [-3.44, 0.46]
Total (95% CI)                 -2.68 [-4.77, -0.59]

Heterogeneity: [[tau].sup.2] = 6.14; [chi square] = 84.58,
df = 5 (P < 0.00001); [I.sup.2] = 94%

Test for overall effect: Z = 2.52 (P = 0.01)

Figure 8: BI comparison at 90 days.

                          Naoxueshu         Control        Weight

Study or subgroup      Events    Total   Events    Total

Chen et al. 2016         23       35       15       32      30.2%
zhou et al. 2015         56       87       34       83      69.8%

Total (95% CI)                    122               115    100.0%

Total events             79                49

                           Odds ratio
                        M-H, fixed, 95% CI
Study or subgroup

Chen et al. 2016         2.17 [0.81, 5.81]
zhou et al. 2015         2.60 [1.40, 4.84]

Total (95% CI)           2.47 [1.46, 4.18]

Total events

Heterogeneity: [chi square] = 0.09, df = 1 (P = 0.76);
[I.sup.2] = 0%

Test for overall effect: Z = 3.39 (P = 0.0007)

Figure 9: Treatment efficiency comparison.

                                  Naoxueshu         Control

Study or subgroup              Events    Total    Events     Total

Chen et al. 2016                 28       35        20        32
Gu and Ma 2010                   30       32        21        30
Miao and Yan 2014                34       35        27        34
Wang and Ding 2014 (2)           42       43        37        43
Xie et al. 2007                  272      310       96        130
Y. Yuan and D. Yuan 2012         58       60        26        30

Total (95% CI)                            515                 299
Total events                     464                227

Study or subgroup              Weight    M-H, fixed, 95% CI

Chen et al. 2016               16.8%      2.40 [0.80, 7.17]
Gu and Ma 2010                  5.4%     6.43 [1.26, 32.83]
Miao and Yan 2014               3.1%     8.81 [1.02, 76.08]
Wang and Ding 2014 (2)          3.5%     6.81 [0.78, 59.21]
Xie et al. 2007                66.6%      2.54 [1.51, 4.26]
Y. Yuan and D. Yuan 2012        4.6%     4.46 [0.77, 25.91]

Total (95% CI)                 100.0%     3.16 [2.09, 4.76]
Total events

Heterogeneity: [chi square] = 3.17, df = 5 (P = 0.67);
[I.sup.2] = 0%

Test for overall effect: Z = 5.48 (P < 0.00001)
COPYRIGHT 2017 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Wu, Lijun; Li, Yanda; Wang, Xiaofeng; Ren, Xiaomeng; Zhu, Haiyan; Sun, Yikun; Xing, Yanwei; Zhu, Lin
Publication:BioMed Research International
Article Type:Report
Date:Jan 1, 2017
Previous Article:New Mydriasis-Free Electroretinogram Recorded with Skin Electrodes in Healthy Subjects.
Next Article:In Vitro Evaluation of Antimicrobial Activity of Alimentary Canal Extracts from the Red Palm Weevil, Rhynchophorus ferrugineus Olivier Larvae.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |